vs
ICU MEDICAL INC（ICUI）与ROYAL GOLD INC（RGLD）财务数据对比。点击上方公司名可切换其他公司
ICU MEDICAL INC的季度营收约是ROYAL GOLD INC的1.4倍（$540.7M vs $375.3M），ROYAL GOLD INC净利率更高（24.9% vs -2.9%，领先27.9%），ROYAL GOLD INC同比增速更快（85.3% vs -14.1%），过去两年ROYAL GOLD INC的营收复合增速更高（58.8% vs -2.3%）
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
Royal Gold Inc.是全球领先的贵金属流权与特许权经营企业，收购并管理多元化的矿业项目流权、净熔炼收益特许权及相关权益，资产覆盖黄金、白银、铜等品类，业务遍及多地区，无需直接承担采矿运营风险。
ICUI vs RGLD — 直观对比
营收规模更大
ICUI
是对方的1.4倍
$375.3M
营收增速更快
RGLD
高出99.4%
-14.1%
净利率更高
RGLD
高出27.9%
-2.9%
两年增速更快
RGLD
近两年复合增速
-2.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $540.7M | $375.3M |
| 净利润 | $-15.7M | $93.6M |
| 毛利率 | 37.5% | 64.6% |
| 营业利润率 | 1.0% | 56.2% |
| 净利率 | -2.9% | 24.9% |
| 营收同比 | -14.1% | 85.3% |
| 净利润同比 | 34.0% | -12.8% |
| 每股收益（稀释后） | $-0.63 | $1.04 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ICUIRGLD
| Q4 25 | $540.7M | $375.3M | ||
| Q3 25 | $537.0M | $252.1M | ||
| Q2 25 | $548.9M | $209.6M | ||
| Q1 25 | $604.7M | $193.4M | ||
| Q4 24 | $629.8M | $202.6M | ||
| Q3 24 | $589.1M | $193.8M | ||
| Q2 24 | $596.5M | $174.1M | ||
| Q1 24 | $566.7M | $148.9M |
净利润ICUIRGLD
| Q4 25 | $-15.7M | $93.6M | ||
| Q3 25 | $-3.4M | $126.8M | ||
| Q2 25 | $35.3M | $132.3M | ||
| Q1 25 | $-15.5M | $113.5M | ||
| Q4 24 | $-23.8M | $107.4M | ||
| Q3 24 | $-33.0M | $96.2M | ||
| Q2 24 | $-21.4M | $81.2M | ||
| Q1 24 | $-39.5M | $47.2M |
毛利率ICUIRGLD
| Q4 25 | 37.5% | 64.6% | ||
| Q3 25 | 37.4% | 73.6% | ||
| Q2 25 | 37.9% | 72.6% | ||
| Q1 25 | 34.7% | 69.4% | ||
| Q4 24 | 36.1% | 70.3% | ||
| Q3 24 | 34.8% | 66.6% | ||
| Q2 24 | 34.8% | 64.7% | ||
| Q1 24 | 32.7% | 58.4% |
营业利润率ICUIRGLD
| Q4 25 | 1.0% | 56.2% | ||
| Q3 25 | 2.6% | 64.4% | ||
| Q2 25 | 1.9% | 67.7% | ||
| Q1 25 | 2.1% | 63.6% | ||
| Q4 24 | 6.0% | 65.9% | ||
| Q3 24 | 1.4% | 61.3% | ||
| Q2 24 | 1.3% | 58.6% | ||
| Q1 24 | -1.9% | 50.7% |
净利率ICUIRGLD
| Q4 25 | -2.9% | 24.9% | ||
| Q3 25 | -0.6% | 50.3% | ||
| Q2 25 | 6.4% | 63.1% | ||
| Q1 25 | -2.6% | 58.7% | ||
| Q4 24 | -3.8% | 53.0% | ||
| Q3 24 | -5.6% | 49.7% | ||
| Q2 24 | -3.6% | 46.6% | ||
| Q1 24 | -7.0% | 31.7% |
每股收益（稀释后）ICUIRGLD
| Q4 25 | $-0.63 | $1.04 | ||
| Q3 25 | $-0.14 | $1.92 | ||
| Q2 25 | $1.43 | $2.01 | ||
| Q1 25 | $-0.63 | $1.72 | ||
| Q4 24 | $-0.97 | $1.63 | ||
| Q3 24 | $-1.35 | $1.46 | ||
| Q2 24 | $-0.88 | $1.23 | ||
| Q1 24 | $-1.63 | $0.72 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $233.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.1B | $7.2B |
| 总资产 | $4.1B | $9.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ICUIRGLD
| Q4 25 | — | $233.7M | ||
| Q3 25 | — | $172.8M | ||
| Q2 25 | — | $248.2M | ||
| Q1 25 | — | $240.8M | ||
| Q4 24 | $308.6M | $195.5M | ||
| Q3 24 | $312.5M | $127.9M | ||
| Q2 24 | $302.6M | $74.2M | ||
| Q1 24 | $251.4M | $137.9M |
总债务ICUIRGLD
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | $50.0M | ||
| Q1 24 | — | — |
股东权益ICUIRGLD
| Q4 25 | $2.1B | $7.2B | ||
| Q3 25 | $2.1B | $3.4B | ||
| Q2 25 | $2.1B | $3.3B | ||
| Q1 25 | $2.0B | $3.2B | ||
| Q4 24 | $2.0B | $3.1B | ||
| Q3 24 | $2.0B | $3.0B | ||
| Q2 24 | $2.0B | $3.0B | ||
| Q1 24 | $2.1B | $2.9B |
总资产ICUIRGLD
| Q4 25 | $4.1B | $9.5B | ||
| Q3 25 | $4.1B | $4.5B | ||
| Q2 25 | $4.1B | $3.6B | ||
| Q1 25 | $4.2B | $3.5B | ||
| Q4 24 | $4.2B | $3.4B | ||
| Q3 24 | $4.3B | $3.3B | ||
| Q2 24 | $4.3B | $3.3B | ||
| Q1 24 | $4.3B | $3.3B |
负债/权益比ICUIRGLD
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.02× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $60.6M | $241.7M |
| 自由现金流经营现金流 - 资本支出 | $36.0M | — |
| 自由现金流率自由现金流/营收 | 6.6% | — |
| 资本支出强度资本支出/营收 | 4.6% | — |
| 现金转化率经营现金流/净利润 | — | 2.58× |
| 过去12个月自由现金流最近4个季度 | $91.8M | — |
8季度趋势，按日历期对齐
经营现金流ICUIRGLD
| Q4 25 | $60.6M | $241.7M | ||
| Q3 25 | $56.7M | $174.0M | ||
| Q2 25 | $11.2M | $152.8M | ||
| Q1 25 | $51.3M | $136.4M | ||
| Q4 24 | $40.2M | $141.1M | ||
| Q3 24 | $36.1M | $136.7M | ||
| Q2 24 | $82.0M | $113.5M | ||
| Q1 24 | $45.8M | $138.3M |
自由现金流ICUIRGLD
| Q4 25 | $36.0M | — | ||
| Q3 25 | $27.6M | — | ||
| Q2 25 | $-8.5M | — | ||
| Q1 25 | $36.7M | — | ||
| Q4 24 | $16.1M | — | ||
| Q3 24 | $16.2M | — | ||
| Q2 24 | $62.5M | — | ||
| Q1 24 | $29.9M | — |
自由现金流率ICUIRGLD
| Q4 25 | 6.6% | — | ||
| Q3 25 | 5.1% | — | ||
| Q2 25 | -1.5% | — | ||
| Q1 25 | 6.1% | — | ||
| Q4 24 | 2.6% | — | ||
| Q3 24 | 2.7% | — | ||
| Q2 24 | 10.5% | — | ||
| Q1 24 | 5.3% | — |
资本支出强度ICUIRGLD
| Q4 25 | 4.6% | — | ||
| Q3 25 | 5.4% | — | ||
| Q2 25 | 3.6% | — | ||
| Q1 25 | 2.4% | — | ||
| Q4 24 | 3.8% | — | ||
| Q3 24 | 3.4% | — | ||
| Q2 24 | 3.3% | — | ||
| Q1 24 | 2.8% | — |
现金转化率ICUIRGLD
| Q4 25 | — | 2.58× | ||
| Q3 25 | — | 1.37× | ||
| Q2 25 | 0.32× | 1.15× | ||
| Q1 25 | — | 1.20× | ||
| Q4 24 | — | 1.31× | ||
| Q3 24 | — | 1.42× | ||
| Q2 24 | — | 1.40× | ||
| Q1 24 | — | 2.93× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
RGLD
| Gold | $216.9M | 58% |
| Pueblo Viejo | $47.3M | 13% |
| Andacollo | $32.6M | 9% |
| Silver | $32.1M | 9% |
| Other | $27.2M | 7% |
| Copper | $13.7M | 4% |
| Cortez Legacy Zone | $5.4M | 1% |
